An opioid settlement charge pushed Albertsons Cos. to a fourth-quarter net loss even as sales edged higher and digital growth stayed in double digits. For the 13 weeks to 28 February, net sales and other revenue reached $20.3 billion against $18.8 billion a year earlier, though roughly $1.4 billion of that increase came from an extra week in the quarter.
Identical sales rose 0.7%, driven by pharmacy, and digital sales grew 16%. The company posted a net loss of $480.8 million, or 94 cents per share, compared with net income of $171.8 million, or 29 cents, in the prior-year quarter. The loss included an after-tax net expense of $599.8 million, or $1.18 per share, tied to an opioid settlement framework. Albertsons has agreed a $774 million framework resolving substantially all opioid-related claims brought by state, local and tribal government entities, and company officials said the settlement is not an admission of wrongdoing or liability. Chief executive Susan Morris called fiscal 2025 a year of strong execution and resilience, finishing with solid adjusted EBITDA despite significant revenue headwinds in pharmacy, and pointed to investment in the customer value proposition, digital and loyalty. For the full year, net sales and other revenue were $83.2 billion against $80.4 billion, net income was $217.4 million, or 40 cents per diluted share, down from $958.6 million and $1.64, identical sales grew 2% and digital sales rose 21%.
Why it matters for the pet industry
Retail pharmacy is a live regulatory frontier, and a growing share of veterinary prescriptions is filled at human pharmacy counters. A settlement framework of this scale hardens controlled-substance dispensing protocols, documentation and audit trails across large chains, and those controls do not distinguish between a human and an animal patient. Clinics should expect more verification calls, more rejected or delayed scripts and longer turnaround on pain-management medications routed to grocery pharmacy.
Strategically, pharmacy was also the engine of identical sales growth here. That makes the counter a traffic asset worth defending, and pet medication is one of the few underexploited adjacencies grocery pharmacy can add, but only where compliance capacity exists to absorb it.
What to watch
- Final participation levels in the $774 million framework and any extension to additional claimant groups.
- Whether pharmacy keeps driving identical sales growth across the coming quarterly reports, or the headwinds deepen.
- Chain pharmacy policy changes affecting veterinary prescription fulfillment and clinic dispensing turnaround.
FAQ
What was Albertsons’ Q4 net loss and settlement charge?
Albertsons reported a fourth-quarter net loss of $480.8 million, or 94 cents per share, against net income of $171.8 million a year earlier. The loss included a $599.8 million after-tax charge tied to a $774 million opioid settlement framework resolving substantially all opioid-related government claims.
How does the Albertsons opioid settlement affect pet prescriptions?
A growing share of veterinary prescriptions is filled at human pharmacy counters, and Albertsons’ $774 million settlement framework hardens controlled-substance dispensing protocols, documentation and audit trails. Those controls do not distinguish between human and animal patients, so clinics should expect more verification calls and delayed pain-management scripts.
Will pharmacy controls tighten for veterinary scripts?
Veterinary clinics should expect tighter verification, more rejected or delayed scripts and longer turnaround on pain-management medications routed through retail pharmacy. As settlement-driven controls spread across large chains like Albertsons, pet prescribers must build buffer time into treatment plans rather than relying on same-day human-pharmacy fulfillment.
Source intelligence adapted for the GlobalPetIndex pet-industry audience. Original publication: external brief.
